Lilly(Eli) & Company
NYSE: LLY
$834.02
+$2.48 (+0.3%)
Real Time Data Delayed 15 Min.
LLY Articles
AuthorDendreon Corp. (NASDAQ: DNDN), maker of prostate cancer drug Provenge, is once again rumored to be a takeover target. As Streetinsider.com points out, the company’s new chairman presided over...
Published:
By now, most investors know that the large hedge funds are run by billionaires rather than millionaires. What many investors might not know is that some hedge funds are reaching the size of large...
Published:
Last Updated:
All three major indexes opened higher this morning, but the strength didn’t last as the Chicago PMI number failed to meet expectations and came in lower even than last month’s reading. The lower...
Published:
Last Updated:
Greece will announce its new government today. (Reuters) Inflation in China drops in October. (Reuters) Olympus investment losses may have gone above $1 billion. (Reuters) Silvio Berlusconi leaves as...
Published:
Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better than analysts expected, but worries persist that the company will be hit...
Published:
Last Updated:
Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability. One way to make up for the loss is to get US Food & Drug...
Published:
Merck & Co. Inc. (NYSE: MRK) released second-quarter results last Friday and Pfizer Inc. (NYSE: PFE) reported this morning. The results of both drug behemoths are largely in line with analysts...
Published:
Apple Inc (NASDAQ: AAPL) reported better than expected earnings and its shares soared (Reuters) Yahoo!’s (NASDAQ: YHOO) revenue fell (Reuters) A settlement of the debate over the U.S. debt pushed...
Published:
The number of stocks that made substantial gains for the week was limited. The great exception to that rule was Petrohawk Energy Corporation Co (NYSE: HK) which jumped 62.5% on Friday after a buyout...
Published:
Many drug companies face a what is called a patent cliff ahead, where the Big Pharma players will have key drugs go off-patent and there will be new generic competition. While this is a challenge...
Published:
We may have just witnessed an oversold bounce in the stock market, or we may be in for more days of recovery. The markets are flirting with six weeks of negative performance and one day is not...
Published:
Last Updated:
NYSE (NYSE: NYX) was thrashed as Nasdaq (NASDAQ: NDAQ) and ICE pulled their buyout offer due to regulatory concerns. Hewlett-Packard (NYSE: HPQ) was savaged by the press as information from its CEO...
Published: